BioNTech (BNTX)
(Delayed Data from NSDQ)
$107.34 USD
-0.16 (-0.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $107.40 +0.06 (0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTX 107.34 -0.16(-0.15%)
Will BNTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Buy, Sell or Hold Pfizer Stock? Key Tips Ahead of Q2 Earnings
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know
Other News for BNTX
Earnings week ahead: AMD, PLTR, PFE, DIS, O, ET, SHOP, GILD, MCD, CAT, VTRS, BP, UBER, CGC, and more
Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)
BioNTech Q2 2025 Earnings Preview
Experts helping vaccine advisors are reportedly ousted at CDC
A Look Ahead: BioNTech's Earnings Forecast